MedtronicMDT
About: One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Employees: 95,000
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
29% more call options, than puts
Call options by funds: $793M | Put options by funds: $614M
1% more repeat investments, than reductions
Existing positions increased: 862 | Existing positions reduced: 850
0.99% more ownership
Funds ownership: 82.87% [Q1] → 83.86% (+0.99%) [Q2]
1% less first-time investments, than exits
New positions opened: 144 | Existing positions closed: 145
3% less capital invested
Capital invested by funds: $97B [Q1] → $93.6B (-$3.38B) [Q2]
2% less funds holding
Funds holding: 2,140 [Q1] → 2,089 (-51) [Q2]
28% less funds holding in top 10
Funds holding in top 10: 43 [Q1] → 31 (-12) [Q2]
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
11 analyst ratings
Argus Research David Toung | 25%upside $115 | Buy Maintained | 26 Aug 2025 |
Citigroup Joanne Wuensch | 10%upside $101 | Buy Maintained | 21 Aug 2025 |
Truist Securities Richard Newitter | 4%upside $96 | Hold Maintained | 21 Aug 2025 |
Wells Fargo Larry Biegelsen | 8%upside $100 | Overweight Maintained | 20 Aug 2025 |
UBS Danielle Antalffy | 3%upside $95 | Neutral Maintained | 20 Aug 2025 |
Financial journalist opinion
Based on 51 articles about MDT published over the past 30 days
